$CELG Company News
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Tech ETF QQQ gains on Facebook, other earnings 8:48 a.m. July 25, 2013 - Victor Reklaitis
Celgene profit up 30% as Revlimid sales increase 6:55 a.m. July 25, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 5:37 p.m. July 24, 2013 - blogs.marketwatch.com
The Next 24: Internet Stocks Jump 3:39 p.m. July 24, 2013 - MarketWatch
Epizyme Up on Milestone Payments - Analyst Blog 12:10 p.m. Today - Zacks.com
5 Stocks Improving Performance Of The Health Care Sector 12:03 p.m. Today - TheStreet.com
Abraxane Label Expansion Lifts Celgene - Analyst Blog 11:30 a.m. Today - Zacks.com
Nomura starts coverage on multiple biotechs 10:46 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Market's Message 8:25 p.m. Jan. 7, 2014 - TheStreet.com
Top Funds Like Facebook And Health Care Stocks 5:59 p.m. Jan. 7, 2014 - Investors Business Daily
Pharmacyclics, Valeant, Celgene Up On Bullish News 5:45 p.m. Jan. 7, 2014 - Investors Business Daily
Best Ideas for 2014 (Part 2) 3:29 p.m. Jan. 7, 2014 - RealMoney.com
Is the Biotech Boom Over? 10:58 a.m. Jan. 7, 2014 - Barrons.com
Celgene Gets Good News On Two Cancer Drugs; Stock Up 10:00 a.m. Jan. 7, 2014 - Investors Business Daily
Epizyme rallies as company hits milestones in partnerships 8:02 a.m. Jan. 7, 2014 - Seeking Alpha
EU OKs Celgene pancreatic cancer drug 7:02 a.m. Jan. 7, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: CELG SIRI GNK NEM 6:00 a.m. Jan. 7, 2014 - TheStreet.com
Celgene Announces EC Approval for ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer 5:09 a.m. Jan. 7, 2014 - benzinga.com
'Fast Money' Recap: Watching China 5:00 a.m. Jan. 7, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Profiting From Down Days 8:20 p.m. Jan. 6, 2014 - TheStreet.com
Cancer Drug Royalties: Celgene Battles Boston Hospital 11:35 a.m. Jan. 6, 2014 - Wall St. Cheat Sheet
Citi's top biotech picks include Biogen, Gilead, and Celgene 8:33 a.m. Jan. 6, 2014 - Seeking Alpha
Celgene, Boston Children's Hospital in dispute over cancer drug payments 8:08 a.m. Jan. 6, 2014 - Seeking Alpha
Top Analyst Downgrades, Stocks to Sell: Apple, Twitter, First Solar and More 7:53 a.m. Jan. 6, 2014 - 247WallSt.com
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Tech ETF QQQ gains on Facebook, other earnings 8:48 a.m. July 25, 2013 - Victor Reklaitis
Celgene profit up 30% as Revlimid sales increase 6:55 a.m. July 25, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 5:37 p.m. July 24, 2013 - blogs.marketwatch.com
The Next 24: Internet Stocks Jump 3:39 p.m. July 24, 2013 - MarketWatch
Epizyme Up on Milestone Payments - Analyst Blog 12:10 p.m. Today - Zacks.com
5 Stocks Improving Performance Of The Health Care Sector 12:03 p.m. Today - TheStreet.com
Abraxane Label Expansion Lifts Celgene - Analyst Blog 11:30 a.m. Today - Zacks.com
Nomura starts coverage on multiple biotechs 10:46 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Market's Message 8:25 p.m. Jan. 7, 2014 - TheStreet.com
Top Funds Like Facebook And Health Care Stocks 5:59 p.m. Jan. 7, 2014 - Investors Business Daily
Pharmacyclics, Valeant, Celgene Up On Bullish News 5:45 p.m. Jan. 7, 2014 - Investors Business Daily
Best Ideas for 2014 (Part 2) 3:29 p.m. Jan. 7, 2014 - RealMoney.com
Is the Biotech Boom Over? 10:58 a.m. Jan. 7, 2014 - Barrons.com
Celgene Gets Good News On Two Cancer Drugs; Stock Up 10:00 a.m. Jan. 7, 2014 - Investors Business Daily
Epizyme rallies as company hits milestones in partnerships 8:02 a.m. Jan. 7, 2014 - Seeking Alpha
EU OKs Celgene pancreatic cancer drug 7:02 a.m. Jan. 7, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: CELG SIRI GNK NEM 6:00 a.m. Jan. 7, 2014 - TheStreet.com
Celgene Announces EC Approval for ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer 5:09 a.m. Jan. 7, 2014 - benzinga.com
'Fast Money' Recap: Watching China 5:00 a.m. Jan. 7, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Profiting From Down Days 8:20 p.m. Jan. 6, 2014 - TheStreet.com
Cancer Drug Royalties: Celgene Battles Boston Hospital 11:35 a.m. Jan. 6, 2014 - Wall St. Cheat Sheet
Citi's top biotech picks include Biogen, Gilead, and Celgene 8:33 a.m. Jan. 6, 2014 - Seeking Alpha
Celgene, Boston Children's Hospital in dispute over cancer drug payments 8:08 a.m. Jan. 6, 2014 - Seeking Alpha
Top Analyst Downgrades, Stocks to Sell: Apple, Twitter, First Solar and More 7:53 a.m. Jan. 6, 2014 - 247WallSt.com
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
